AAIC 2025 Abstract
Utilizing the Brain Vasculature to Improve Delivery and Safety of the Next Generation of AD Therapeutics
Experiments in animalsInterventions
Abstract
Background: Although the first generation of immunotherapies for Alzheimer’s disease (AD) are now clinically approved, amyloid‐related imaging abnormalities (ARIA) remain a major safety problem for this class of drugs.
